1. Home
  2. DYN vs MRX Comparison

DYN vs MRX Comparison

Compare DYN & MRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DYN
  • MRX
  • Stock Information
  • Founded
  • DYN 1984
  • MRX 2005
  • Country
  • DYN United States
  • MRX United Kingdom
  • Employees
  • DYN N/A
  • MRX N/A
  • Industry
  • DYN Medicinal Chemicals and Botanical Products
  • MRX
  • Sector
  • DYN Health Care
  • MRX
  • Exchange
  • DYN Nasdaq
  • MRX NYSE
  • Market Cap
  • DYN 2.6B
  • MRX 2.2B
  • IPO Year
  • DYN 2020
  • MRX 2024
  • Fundamental
  • Price
  • DYN $14.13
  • MRX $33.75
  • Analyst Decision
  • DYN Strong Buy
  • MRX Strong Buy
  • Analyst Count
  • DYN 10
  • MRX 8
  • Target Price
  • DYN $50.70
  • MRX $33.25
  • AVG Volume (30 Days)
  • DYN 1.8M
  • MRX 316.7K
  • Earning Date
  • DYN 03-04-2025
  • MRX 02-25-2025
  • Dividend Yield
  • DYN N/A
  • MRX 0.83%
  • EPS Growth
  • DYN N/A
  • MRX 2.80
  • EPS
  • DYN N/A
  • MRX 2.51
  • Revenue
  • DYN N/A
  • MRX $1,539,450,000.00
  • Revenue This Year
  • DYN N/A
  • MRX N/A
  • Revenue Next Year
  • DYN N/A
  • MRX $7.14
  • P/E Ratio
  • DYN N/A
  • MRX $13.43
  • Revenue Growth
  • DYN N/A
  • MRX N/A
  • 52 Week Low
  • DYN $14.03
  • MRX $18.13
  • 52 Week High
  • DYN $47.45
  • MRX $34.19
  • Technical
  • Relative Strength Index (RSI)
  • DYN 19.54
  • MRX N/A
  • Support Level
  • DYN $14.79
  • MRX N/A
  • Resistance Level
  • DYN $15.90
  • MRX N/A
  • Average True Range (ATR)
  • DYN 1.55
  • MRX 0.00
  • MACD
  • DYN -0.82
  • MRX 0.00
  • Stochastic Oscillator
  • DYN 0.82
  • MRX 0.00

About DYN Dyne Therapeutics Inc.

Dyne Therapeutics Inc is a biotechnology company focused on providing therapeutics for patients with genetically driven diseases. The company overcomes the limitations of muscle tissue delivery and modern oligonucleotide therapeutics for muscle diseases. The company is developing therapies for muscle disorders like Myotonic dystrophy, Duchenne muscular dystrophy, and Facioscapulohumeral muscular dystrophy. The company's product candidates are DYNE-101 and DYNE-251, both are in the ongoing phase 1/2 clinical trial.

About MRX MAREX GROUP PLC

Marex Group PLC is a company that offers a diversified global financial services platform providing essential liquidity, market access and infrastructure services to clients across energy, commodities and financial markets. It provides critical services to the clients by connecting them to global exchanges and providing a range of execution and hedging services across a range of its asset and products. They operate in a large and fragmented market with significant infrastructure requirements and regulatory and technological complexity, resulting in high barriers to entry.

Share on Social Networks: